Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

CORONA REMEDIES LTD.

NSE : NABSE : 544644ISIN CODE : INE02ZQ01018Industry : Pharmaceuticals & DrugsHouse : Private

BSE0.000 (0 %)

PREV CLOSE ( ) NA

OPEN PRICE ( ) 0.00

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 0

TODAY'S LOW / HIGH ( )0.00 0.00

52 WK LOW / HIGH ( ) 00

NSE

This Company is not listed in NSE

Select year

(Rs.in Million)

Particulars

Mar 2025

Mar 2024

Mar 2023

Profit Before Tax

1985.33

1184.81

1108.87

Adjustment

523.00

468.67

225.50

Changes In working Capital

-170.61

93.15

-49.15

Cash Flow after changes in Working Capital

2337.72

1746.63

1285.22

Cash Flow from Operating Activities

1904.96

1567.58

1027.00

Cash Flow from Investing Activities

-838.40

-2666.43

-502.45

Cash Flow from Financing Activities

-1065.89

985.45

-447.47

Net Cash Inflow / Outflow

0.67

-113.40

77.08

Opening Cash & Cash Equivalents

31.56

144.94

68.24

Cash & Cash Equivalent on Amalgamation / Take over / Merger

Cash & Cash Equivalent of Subsidiaries under liquidations

Translation adjustment on reserves / op cash balalces frgn subsidiaries

Effect of Foreign Exchange Fluctuations

0.02

-0.38

Closing Cash & Cash Equivalent

32.23

31.56

144.94